Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C10H14N4O3 |
| Molecular Weight | 238.2432 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(O)CN1C=NC2=C1C(=O)N(C)C(=O)N2C
InChI
InChIKey=KYHQZNGJUGFTGR-UHFFFAOYSA-N
InChI=1S/C10H14N4O3/c1-6(15)4-14-5-11-8-7(14)9(16)13(3)10(17)12(8)2/h5-6,15H,4H2,1-3H3
| Molecular Formula | C10H14N4O3 |
| Molecular Weight | 238.2432 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/6291318Curator's Comment: description was created based on several sources, including
http://www.ndrugs.com/?s=ephedrine/proxyphylline
Sources: http://www.ncbi.nlm.nih.gov/pubmed/6291318
Curator's Comment: description was created based on several sources, including
http://www.ndrugs.com/?s=ephedrine/proxyphylline
Proxyphylline is a xanthine derivative that acts as a cardiac stimulant, vasodilator and bronchodilator. In combination with ephedrine it’s used for relief of acute bronchial asthma and for reversible bronchospasm associated with chronic bronchitis and emphysema. Proxyphylline is readily absorbed from the gastrointestinal tract and it’s not converted to theophylline in the body. The clinical studies are agreed with the property of proxyphylline to inhibit the cyclic nucleotide phosphodiesterases.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2363066 Sources: http://www.ncbi.nlm.nih.gov/pubmed/6291318 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Secondary | Novofilin Approved UseUnknown |
|||
| Secondary | Unknown Approved UseUnknown |
|||
| Secondary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
6.87 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6630383/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: DYPHYLLINE |
PROXYPHYLLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3.946 μg/mL |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: EPHEDRINE HYDROCHLORIDE |
PROXYPHYLLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3.588 μg/mL |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: EPHEDRINE HYDROCHLORIDE |
PROXYPHYLLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
59.57 μg × h/mL |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: EPHEDRINE HYDROCHLORIDE |
PROXYPHYLLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
46.38 μg × h/mL |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: EPHEDRINE HYDROCHLORIDE |
PROXYPHYLLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
8.69 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6630383/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: DYPHYLLINE |
PROXYPHYLLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
100% |
PROXYPHYLLINE plasma | Homo sapiens |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Synthesis, pharmacological activity and nitric oxide generation by nitrate derivatives of theophylline. | 2008-05 |
|
| Modifying the release of proxyphylline from PVA hydrogels using surface crosslinking. | 2008-02-12 |
|
| Surface crosslinking for delayed release of proxyphylline from PHEMA hydrogels. | 2008-02-12 |
|
| Hydrophilic molecularly imprinted poly(hydroxyethyl-methacrylate) polymers. | 2006-07 |
|
| The role of the discriminant factor in the assessment and treatment of alcoholic hepatitis. | 2004-04-22 |
|
| Minimization of initial burst in poly(vinyl alcohol) hydrogels by surface extraction and surface-preferential crosslinking. | 2002-11-06 |
|
| Polymer particle erosion controlling drug release. II. Swelling investigations to clarify the release mechanism. | 2002-10-24 |
|
| Kinetic-spectrophotometric determination of theophylline, dyphylline, and proxyphylline by use of partial least-squares regression. | 2002-09 |
|
| Application of micellar electrokinetic chromatography to the quality control of a pharmaceutical preparation containing three bronchodilators. | 2002-02 |
|
| Antianaphylactic and antiasthmatic properties of new piperazinyl 7-(beta-hydroxypropyl)-theophylline derivatives in guinea pigs. | 2002-01-15 |
|
| Multi-component kinetic-spectrophotometric analysis. Selection of wavelength and time ranges. | 2001-07 |
|
| [Effectiveness of proxyphylline in chronic obstructive pulmonary disease (author's transl)]. | 1980-06-20 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/7202475
intravenous: 29 mumol/kgsingle oral: 21 mumol/kg and multiple oral: 21 mumol/kg three times a day
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6291318
Inhibition of cAMP and cGMP hydrolysis in human lung tissue by proxyphylline and its main metabolite 1-methyl-7-(beta-hydroxypropyl)xanthine was compared with theophylline and its metabolite 3-methylxanthine. The Inhibition constant of proxyphylline was 0.06-0.7 mmol/l at low cAMP concentrations and at low and high cGMP concentrations, while it was 1.0 mmol/l at high cAMP concentrations
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:21:20 GMT 2025
by
admin
on
Mon Mar 31 18:21:20 GMT 2025
|
| Record UNII |
13G1DMN4P0
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
R03DA03
Created by
admin on Mon Mar 31 18:21:20 GMT 2025 , Edited by admin on Mon Mar 31 18:21:20 GMT 2025
|
||
|
WHO-VATC |
QR03DB03
Created by
admin on Mon Mar 31 18:21:20 GMT 2025 , Edited by admin on Mon Mar 31 18:21:20 GMT 2025
|
||
|
WHO-VATC |
QR03DA03
Created by
admin on Mon Mar 31 18:21:20 GMT 2025 , Edited by admin on Mon Mar 31 18:21:20 GMT 2025
|
||
|
WHO-ATC |
R03DB03
Created by
admin on Mon Mar 31 18:21:20 GMT 2025 , Edited by admin on Mon Mar 31 18:21:20 GMT 2025
|
||
|
NCI_THESAURUS |
C319
Created by
admin on Mon Mar 31 18:21:20 GMT 2025 , Edited by admin on Mon Mar 31 18:21:20 GMT 2025
|
||
|
NCI_THESAURUS |
C744
Created by
admin on Mon Mar 31 18:21:20 GMT 2025 , Edited by admin on Mon Mar 31 18:21:20 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
86480-51-5
Created by
admin on Mon Mar 31 18:21:20 GMT 2025 , Edited by admin on Mon Mar 31 18:21:20 GMT 2025
|
SUPERSEDED | |||
|
210-028-7
Created by
admin on Mon Mar 31 18:21:20 GMT 2025 , Edited by admin on Mon Mar 31 18:21:20 GMT 2025
|
PRIMARY | |||
|
C80339
Created by
admin on Mon Mar 31 18:21:20 GMT 2025 , Edited by admin on Mon Mar 31 18:21:20 GMT 2025
|
PRIMARY | |||
|
CHEMBL37390
Created by
admin on Mon Mar 31 18:21:20 GMT 2025 , Edited by admin on Mon Mar 31 18:21:20 GMT 2025
|
PRIMARY | |||
|
34906
Created by
admin on Mon Mar 31 18:21:20 GMT 2025 , Edited by admin on Mon Mar 31 18:21:20 GMT 2025
|
PRIMARY | RxNorm | ||
|
m9284
Created by
admin on Mon Mar 31 18:21:20 GMT 2025 , Edited by admin on Mon Mar 31 18:21:20 GMT 2025
|
PRIMARY | Merck Index | ||
|
PROXYPHYLLINE
Created by
admin on Mon Mar 31 18:21:20 GMT 2025 , Edited by admin on Mon Mar 31 18:21:20 GMT 2025
|
PRIMARY | |||
|
SUB10153MIG
Created by
admin on Mon Mar 31 18:21:20 GMT 2025 , Edited by admin on Mon Mar 31 18:21:20 GMT 2025
|
PRIMARY | |||
|
4977
Created by
admin on Mon Mar 31 18:21:20 GMT 2025 , Edited by admin on Mon Mar 31 18:21:20 GMT 2025
|
PRIMARY | |||
|
C003237
Created by
admin on Mon Mar 31 18:21:20 GMT 2025 , Edited by admin on Mon Mar 31 18:21:20 GMT 2025
|
PRIMARY | |||
|
DB13449
Created by
admin on Mon Mar 31 18:21:20 GMT 2025 , Edited by admin on Mon Mar 31 18:21:20 GMT 2025
|
PRIMARY | |||
|
969
Created by
admin on Mon Mar 31 18:21:20 GMT 2025 , Edited by admin on Mon Mar 31 18:21:20 GMT 2025
|
PRIMARY | |||
|
163343
Created by
admin on Mon Mar 31 18:21:20 GMT 2025 , Edited by admin on Mon Mar 31 18:21:20 GMT 2025
|
PRIMARY | |||
|
100000080861
Created by
admin on Mon Mar 31 18:21:20 GMT 2025 , Edited by admin on Mon Mar 31 18:21:20 GMT 2025
|
PRIMARY | |||
|
603-00-9
Created by
admin on Mon Mar 31 18:21:20 GMT 2025 , Edited by admin on Mon Mar 31 18:21:20 GMT 2025
|
PRIMARY | |||
|
DTXSID5023536
Created by
admin on Mon Mar 31 18:21:20 GMT 2025 , Edited by admin on Mon Mar 31 18:21:20 GMT 2025
|
PRIMARY | |||
|
13G1DMN4P0
Created by
admin on Mon Mar 31 18:21:20 GMT 2025 , Edited by admin on Mon Mar 31 18:21:20 GMT 2025
|
PRIMARY | |||
|
2323
Created by
admin on Mon Mar 31 18:21:20 GMT 2025 , Edited by admin on Mon Mar 31 18:21:20 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE | |||
|
|
ENANTIOMER -> RACEMATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |